X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AN2025 (buparlisib ) is an oral pan-PI3K inhibitor, It is being evaluated in combination with paclitaxel for the treatment of recurrent or metastatic head and neck squamous cell carcinoma.
Lead Product(s): Buparlisib,Paclitaxel
Therapeutic Area: Oncology Product Name: AN2025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2023
Details:
The net proceeds will fund the ongoing registrational trial for AN2025 (buparlisib), an oral pan-PI3K inhibitor that targets all class I PI3K isoforms, the milestone payments in connection with development of AN2025 and the commercial launch, if approved, of AN2025.
Lead Product(s): Buparlisib,Paclitaxel
Therapeutic Area: Oncology Product Name: AN2025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.
Deal Size: $57.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 03, 2023
Details:
The net proceeds will fund the ongoing registrational trial for AN2025 (buparlisib), an oral pan-PI3K inhibitor that targets all class I PI3K isoforms, the milestone payments in connection with development of AN2025 and the commercial launch, if approved, of AN2025.
Lead Product(s): Buparlisib,Paclitaxel
Therapeutic Area: Oncology Product Name: AN2025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.
Deal Size: $106.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 29, 2023
Details:
The collaboration aims to focus on identifying subjects that could derive benefit from AN2025 (buparlisib) treatment in metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) patients and will expand to other indications and clinical trials.
Lead Product(s): Buparlisib,Paclitaxel
Therapeutic Area: Oncology Product Name: AN2025
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nucleai
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 31, 2023
Details:
In IND-213, HR+/HER2- breast cancer patients treated with Reolysin (pelareorep) and paclitaxel showed a statistically significant, near doubling of overall survival compared to those treated with paclitaxel alone.
Lead Product(s): Pelareorep,Paclitaxel,Avelumab
Therapeutic Area: Oncology Product Name: Reolysin
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Oncolytics Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
This includes the rights and interests of Adlai Nortye in the development, manufacturing and commercialization of AN4005 and AN3025 in Greater China, and AN1005, AN6015 and AN9015 worldwide.
Lead Product(s): AN4005
Therapeutic Area: Oncology Product Name: AN4005
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Xiamen Biotime Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 26, 2022
Details:
BRACELET-1, is ongoing and evaluates pelareorep-paclitaxel combination therapy both with and without a checkpoint inhibitor used in Chinese patients with advanced or metastatic breast cancer.
Lead Product(s): Pelareorep,Paclitaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Oncolytics Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2021
Details:
First patient has been dosed in a phase 1b clinical trial (AN0025S0103) to evaluate AN0025, an investigational, potentially first in class oral EP4 antagonist, in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with locally advanced/metastatic solid tumors.
Lead Product(s): AN0025,Pembrolizumab
Therapeutic Area: Oncology Product Name: AN0025
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
